ATE383877T1 - Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren - Google Patents
Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizierenInfo
- Publication number
- ATE383877T1 ATE383877T1 AT00938100T AT00938100T ATE383877T1 AT E383877 T1 ATE383877 T1 AT E383877T1 AT 00938100 T AT00938100 T AT 00938100T AT 00938100 T AT00938100 T AT 00938100T AT E383877 T1 ATE383877 T1 AT E383877T1
- Authority
- AT
- Austria
- Prior art keywords
- hypoxia
- substances
- identification
- transcriptional responses
- modify
- Prior art date
Links
- 206010021143 Hypoxia Diseases 0.000 title abstract 2
- 230000007954 hypoxia Effects 0.000 title abstract 2
- 230000002103 transcriptional effect Effects 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13762599P | 1999-06-04 | 1999-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE383877T1 true ATE383877T1 (de) | 2008-02-15 |
Family
ID=22478315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00938100T ATE383877T1 (de) | 1999-06-04 | 2000-06-02 | Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1198255B1 (de) |
| JP (1) | JP4902915B2 (de) |
| AT (1) | ATE383877T1 (de) |
| CA (1) | CA2376438A1 (de) |
| DE (1) | DE60037813T2 (de) |
| ES (1) | ES2299427T3 (de) |
| PT (1) | PT1198255E (de) |
| WO (1) | WO2000074725A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0013655D0 (en) * | 2000-06-05 | 2000-07-26 | Prolifix Ltd | Therapeutic compounds |
| US7919274B2 (en) * | 2001-03-20 | 2011-04-05 | Dana-Farber Cancer Institute, Inc. | Light-emitting fusion proteins and diagnostic and therapeutic methods therefor |
| AT500023B1 (de) * | 2001-09-27 | 2007-09-15 | Bmt Medizinische Forschung Und | Funktioneller screen für transskriptionsfaktoren |
| US7358043B2 (en) * | 2001-10-16 | 2008-04-15 | Duke University | Proteomic interaction and genomic action determinations in the presence of associated redox state conditions |
| WO2003045440A1 (en) * | 2001-11-28 | 2003-06-05 | Angiogenetics Sweden Ab | Regulation of hypoxia-inducible gene expression with antisense inhibitory pas domain protein |
| AU2003201798A1 (en) * | 2002-01-11 | 2003-09-02 | Angio Genetics Sweden Ab | Hif-1 alpha proteins mutated in the c-terminal transactivation domain |
| GB0206711D0 (en) * | 2002-03-21 | 2002-05-01 | Isis Innovation | HIF Inhibitor |
| GB0211920D0 (en) | 2002-05-23 | 2002-07-03 | Isis Innovations Ltd | Assay |
| US8124582B2 (en) * | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| CN1816327B (zh) * | 2003-06-06 | 2010-09-08 | 菲布罗根公司 | 增强红细胞生成的HIFα稳定剂的应用 |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| WO2005034929A2 (en) * | 2003-10-10 | 2005-04-21 | Fibrogen, Inc. | Tissue remodeling and vascularization |
| JP4682359B2 (ja) * | 2004-12-28 | 2011-05-11 | 独立行政法人産業技術総合研究所 | 神経細胞分化誘導剤 |
| CN100418574C (zh) * | 2005-10-26 | 2008-09-17 | 王成球 | 一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽 |
| KR100711939B1 (ko) | 2005-12-29 | 2007-05-02 | 한국화학연구원 | 형질전환 세포주 및 재조합 바이러스를 이용한 스크리닝방법 |
| DK3026044T3 (en) | 2006-06-26 | 2019-02-18 | Akebia Therapeutics Inc | PROLYL HYDROXYLASE INHIBITORS AND METHODS FOR USE |
| KR100860060B1 (ko) | 2006-10-12 | 2008-09-24 | 한국과학기술연구원 | HIF-1α C-말단 펩타이드와 CBP 또는 p300단백질과의 결합을 정량분석하는 방법 및 상기 방법을이용한 단백질 복합체 형성을 저해하는 억제제의 스크리닝방법 |
| US8815779B2 (en) | 2009-09-16 | 2014-08-26 | SwitchGear Genomics, Inc. | Transcription biomarkers of biological responses and methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5658784A (en) * | 1994-04-14 | 1997-08-19 | Dana-Farber Cancer Institute, Inc. | Nucleic acid encoding transcription factor p300 and uses of p300 |
| CA2236489A1 (en) * | 1997-07-14 | 1999-01-14 | Human Genome Sciences | Novel compounds |
| SE9803891D0 (sv) * | 1998-11-13 | 1998-11-13 | Pharmacia & Upjohn Ab | Protein Variants |
-
2000
- 2000-06-02 WO PCT/US2000/015325 patent/WO2000074725A1/en not_active Ceased
- 2000-06-02 PT PT00938100T patent/PT1198255E/pt unknown
- 2000-06-02 ES ES00938100T patent/ES2299427T3/es not_active Expired - Lifetime
- 2000-06-02 EP EP00938100A patent/EP1198255B1/de not_active Expired - Lifetime
- 2000-06-02 JP JP2001501259A patent/JP4902915B2/ja not_active Expired - Lifetime
- 2000-06-02 CA CA002376438A patent/CA2376438A1/en not_active Abandoned
- 2000-06-02 DE DE60037813T patent/DE60037813T2/de not_active Expired - Lifetime
- 2000-06-02 AT AT00938100T patent/ATE383877T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003501061A (ja) | 2003-01-14 |
| DE60037813D1 (de) | 2008-03-06 |
| EP1198255A1 (de) | 2002-04-24 |
| JP4902915B2 (ja) | 2012-03-21 |
| DE60037813T2 (de) | 2009-01-15 |
| ES2299427T3 (es) | 2008-06-01 |
| EP1198255A4 (de) | 2005-06-15 |
| EP1198255B1 (de) | 2008-01-16 |
| CA2376438A1 (en) | 2000-12-14 |
| PT1198255E (pt) | 2008-04-21 |
| WO2000074725A1 (en) | 2000-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE383877T1 (de) | Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren | |
| EP1231914A4 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| ATE280160T1 (de) | Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität | |
| DE69635821D1 (de) | Vorrichtung zum Bestimmen von Akne, Komedonen und Bakterien auf der menschlichen Haut | |
| ATE483976T1 (de) | Gfats als modifikatoren des p53-wegs und verwendungsverfahren | |
| FI971412L (fi) | Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä | |
| PT1153024E (pt) | 2-amino-6-anilino-purinas e sua utilizacao como medicamentos | |
| UY27940A1 (es) | Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a | |
| DE69929257D1 (de) | Vorrichtung zum Bedrucken und Anbringen von Klebeband an einen Gegenstand. | |
| PT1206474E (pt) | Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2 | |
| TR200100054T2 (tr) | Paroksetin metansülfonat | |
| DE69905170T2 (de) | Thiazolopyrimidinderivate | |
| ATE404667T1 (de) | Chromatin-regulatorgene | |
| DK1313462T3 (da) | Anvendelse af asiatisk syre eller asiaticosid til behandling af cancer | |
| DE60012138D1 (de) | Gerät zur behandlung von fibrillation | |
| TR199802351T2 (xx) | Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi. | |
| DE3850433D1 (de) | Allergiebehandlung und Zusammensetzung dafür. | |
| SE8305160D0 (sv) | Antibakteriella emnen | |
| DE60328931D1 (de) | Wässrige Zubereitungen von Perfluoropolyetherphosphaten und ihre Verwendung für die ölabweisende Behandlung von Papier | |
| PT922703E (pt) | Benzocicloalcenos substituidos e sua utilizacao como substancias com efeito analgesico | |
| ATE328000T1 (de) | Phospholipidester von clofarabin | |
| DE69930844D1 (de) | Inhibitoren von mycobakterien | |
| BR0016941A (pt) | Derivados de aminometil-fenil-ciclohexanona | |
| DE69800080D1 (de) | Antikörper gegen das Prorenin Profragment, reninaktive Substanz die diese enthält und Prorenintest die diese verwendet | |
| DE69911237D1 (de) | Selektion und verwendung von milchsäurebakterienstämmen, die die nicht-spezifische immunität modulieren können |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1198255 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |